NCT01905813View on ClinicalTrials.gov

Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

April 17, 2026

Study Completion Date

April 17, 2026

Conditions
B-cell Malignancies
Interventions
DRUG

INCB040093

Escalating doses starting at 100 mg every day (QD)

DRUG

INCB040093 + itacitinib

INCB040093 dose to be determined at completion of Part 1 of the study + itacitinib at a starting dose of 400 mg, QD with escalations planned up to 600 mg QD.

Trial Locations (6)

Unknown

Birmingham

Jacksonville

Ann Arbor

Rochester

New York

Rochester

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT01905813 - Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies | Biotech Hunter | Biotech Hunter